Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1473-1483

  Rodenhuis, S ^a   Westermann, A ^a   Holtkamp, M J ^a   Nooijen, W J ^a   Baars, J W ^a   van der Wall, E ^a   Slaper Cortenbach, I C ^a   Schornagel, J H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; THIOTEPA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SKIN TOXICITY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0029978783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1473     Document Type: Article

References (34)

1. Peters WP: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, pp 215-230
2. Smith GA, Henderson IC: High-dose chemotherapy with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: The jury is still out, in DeVita VT Jr, Hellmannn S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, pp 201-214
3. Ayash LJ: High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer. Cancer 74:532-535, 1994
4. Ayash LJ, Wheeler C, Fairclough D, et al: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995
5. Livingston RB: Dose intensity and high-dose therapy. Two different concepts. Cancer 74:1177-1183, 1994
6. De Vries EGE, Rodenhuis S, Schouten HC, et al: Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Proc Am Soc Clin Oncol 13:87, 1994 (abstr 151)
7. Van der Wall, Beijnen JH, Rodenhuis S: High-dose chemotherapy regimens for solid tumors. A review. Cancer Treat Rev 21:105-132, 1995
8. Rodenhuis S, Baars J, Schornagel JH, et al: Feasibility and toxicity study of a high-dose chemotherapy regimen incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 3:855-860, 1992
9. Eder JP, Elias A, Shea TC, et al: A phase I-II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239-1245, 1990
10. Van der Wall, Nooijen WJ, Baars JW, et al: High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: A practical approach. Br J Cancer 71:857-862, 1995
11. Rodenhuis S, Van der Wall E, Ten Bokkel Huinink WW, et al: Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest 13:355-362, 1995
12. Rodenhuis S, Vlasveld LT, Dubbelman R, et al: High-dose carboplatin and etoposide without bone marrow support in the salvage treatment of testicular cancer. Ann Oncol 3:463-468, 1992
13. Van der Wall E, Richel DJ, Kusumanto YH, et al: Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann Oncol 4:791-792, 1993
14. Van der Wall E, Richel DJ, Holtkamp MJ, et al: Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral stem cell transplantation: Correlation with graft size. Ann Oncol 5:795-802, 1994
15. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
16. Van Warmerdam LJC, Rodenhuis S, Van Tellingen O, et al: Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35:179-181, 1994
17. Boheim K, Bichler E. Cisplatin-induced ototoxicity: Audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 242:1-6, 1985
18. Van der Lelie J, Baars J, Rodenhuis S, et al: Hemolytic uremic syndrome after high-dose chemotherapy and stem cell support. Cancer (in press)
19. Lotz JP, Machover D, Malassagne B, et al: Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9:1860-1870, 1991
20. Rabinowe SM, Soiffer RJ, Tarbell NJ, et al: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 77:1837-1844, 1991
21. Skipper HE, Schabet FM, Wilcox WS: Experimental evaluation of potential anti-cancer agents XII: On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chem Rep 35:1-111, 1964
22. Skipper HE: Laboratory models: Some historical perspective. Cancer Treat Rep 70:3-7, 1986
23. Teicher BA, Holden SA, Eder JP, et al: Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 49:5994-5998, 1989
24. Norton L, Simon R: Tumor size, sensitivity to therapy and the design of treatment protocols. Cancer Treat Rep 61:1307-1317, 1977
25. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
26. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
27. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994
28. Gianni AM, Bregni M, Siena S, et al: 5-Year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs. MACOP-B therapy for diffuse large-cell lymphomas. Proc Am Soc Clin Oncol 13:373, 1994 (abstr 1263)
29. Goldie JH: Arguments supporting the concept of non-cross-resistant combinations of chemotherapy. Cancer Invest 12:324-328, 1994
30. Day RS: Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 46:3876-3885, 1986
31. Norton L, Day R: Potential innovations in scheduling of cancer chemotherapy, in DeVita VT Jr, Hellmannn S, Rosenberg SA (eds.): Important Advances In Oncology. Philadelphia, PA, Lippincott, 1991, pp 57-72
32. Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors - Prospects. J Clin Oncol 7:515-526, 1989
33. Ragaz J, Goldie J, Coltman A, et al: Kinetics and biological effects of high dose intensity consolidation chemotherapy regimens for solid tumors requiring autologous bone marrow-peripheral stem cell support. Rationale for multiple transplants. Proc Am Soc Clin Oncol 10:108, 1991 (abstr 301)
34. Hill BT: Biochemical and cell kinetic aspects of drug resistance, in Bruchovsky N, Goldie JH (eds): Drug and Hormone Resistance in Neoplasia, vol 1. Boca Raton, FL, CRC, 1982, pp 21-54